Eupraxia Pharmaceuticals announces promising results for EP-104GI in eosinophilic esophagitis trial
Eupraxia Pharmaceuticals Inc., listed on both TSX and NASDAQ under the ticker EPRX, has revealed encouraging results from its ongoing Phase 1b/2a RESOLVE trial. The trial is evaluating EP-104GI, a new treatment for eosinophilic esophagitis (EoE), utilizing the company’s proprietary DiffuSphere technology. Trial Results Show Efficacy and Safety The latest data from the RESOLVE trial’s […]